An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Devimistat (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Cornerstone Pharmaceuticals
- 29 Nov 2018 Results presented in a Rafael Pharmaceuticals media release.
- 14 Jun 2018 According to a Rafael Pharmaceuticals media release, data will be presented at the 23rd Congress of the European Hematology Association.
- 12 Apr 2018 Results published in a Rafael Pharmaceuticals Media Release.